PA
KYNB

Parallel Advisors’s Kyntra Bio KYNB Stock Holding History

Parallel Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$57 – 3409
2023
Q2 		$57 Hold
1
– – ﹤0.01% 3308
2023
Q1 		$560 Hold
1
– – ﹤0.01% 3089
2022
Q4 		$481 Sell
1
-1
-50% -$383 ﹤0.01% 3037
2022
Q3 		$1K Buy
2
+1
+100% +$322 ﹤0.01% 2898
2022
Q2 		$0 Buy
+1
New +$255 ﹤0.01% 3093
2022
Q1 		– Sell
-21
Closed -$8K – 3058
2021
Q4 		$8K Buy
+21
New +$6.54K ﹤0.01% 2196
2021
Q2 		– Sell
-1
Closed -$1K – 2967
2021
Q1 		$1K Hold
1
– – ﹤0.01% 2613
2020
Q4 		$1K Hold
1
– – ﹤0.01% 2422
2020
Q3 		$1K Hold
1
– – ﹤0.01% 2436
2020
Q2 		$1K Hold
1
– – ﹤0.01% 2310
2020
Q1 		$1K Sell
1
-2
-67% -$1.99K ﹤0.01% 2263
2019
Q4 		$3K Hold
3
– – ﹤0.01% 2100
2019
Q3 		$3K Hold
3
– – ﹤0.01% 2052
2019
Q2 		$3K Buy
+3
New +$3.28K ﹤0.01% 1978

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parallel Advisors's KYNB Position: Q3 2023 in Review

Parallel Advisors sold out of Kyntra Bio (KYNB) in Q3 2023, closing a stake of 1 share — an estimated $57 sold.

Parallel Advisors first reported a position in KYNB in Q2 2019 and held it in 14 quarters. The position peaked at $8K in Q4 2021. 110 funds tracked by Wall St. Rank hold KYNB as of Q3 2023.

  • Parallel Advisors reported no remaining Kyntra Bio position as of Q3 2023 after selling out during the quarter.
  • Parallel Advisors sold 1 Kyntra Bio share in Q3 2023, an estimated $57.
  • Parallel Advisors first reported a position in Kyntra Bio in Q2 2019 and held it in 14 quarters.
  • Parallel Advisors's Kyntra Bio position peaked at $8K in Q4 2021.
  • 110 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2023.

Based on Parallel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.